Can RNAi‐mediated hsp90α knockdown in combination with 17‐AAG be a therapy for glioma?

Publisher： John Wiley & Sons Inc

E-ISSN： 2211-5463|3|1|271-278

ISSN： 2211-5463

Source： FEBS Open Bio, Vol.3, Iss.1, 2013-01, pp. : 271-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Hsp90 inhibitor 17‐AAG represses calcium‐induced cytokeratin 1 and 10 expression in HaCaT keratinocytes

By  

FEBS Open Bio, Vol. 2, Iss. 1, 2012-01 ,pp. : 47-50

John Wiley & Sons Inc

Access to resources Recommend Favorite

A comparison of Hsp90α and Hsp90β interactions with cochaperones and substrates

By Taherian Aliakbar   Krone Patrick H.   Ovsenek Nick  

Biochemistry and Cell Biology, Vol. 86, Iss. 1, 2008-02 ,pp. : 37-45

NRC Research Press

Access to resources Recommend Favorite

Glioma: What is the role of c-Myc, hsp90 and telomerase?

By Shervington A.   Cruickshanks N.   Wright H.   Atkinson-Dell R.   Lea R.   Roberts G.   Shervington L.  

Molecular and Cellular Biochemistry, Vol. 283, Iss. 1-2, 2006-02 ,pp. : 1-9

Springer Publishing Company

Access to resources Recommend Favorite

RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences

By Liu Ying Poi   Gruber Jens   Haasnoot Joost   Konstantinova Pavlina   Berkhout Ben  

Nucleic Acids Research, Vol. 37, Iss. 18, 2009-10 ,pp. : 6194-6204

Oxford University Press

Access to resources Recommend Favorite

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

By Maloney Alison   Workman Paul  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 1, 2002-01 ,pp. : 3-24

Informa Healthcare

Access to resources Recommend Favorite